Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Cash & Current Investments (2016 - 2026)

Pharma-Bio Serv's Cash & Current Investments history spans 16 years, with the latest figure at $10.6 million for Q1 2026.

  • For Q1 2026, Cash & Current Investments fell 15.07% year-over-year to $10.6 million; the TTM value through Jan 2026 reached $10.6 million, down 15.07%, while the annual FY2025 figure was $10.9 million, 14.84% down from the prior year.
  • Cash & Current Investments reached $10.6 million in Q1 2026 per PBSV's latest filing, down from $10.9 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $15.9 million in Q1 2024 to a low of $10.4 million in Q2 2025.
  • Average Cash & Current Investments over 5 years is $13.3 million, with a median of $13.5 million recorded in 2024.
  • Peak YoY movement for Cash & Current Investments: increased 3.56% in 2023, then fell 22.75% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $14.5 million in 2022, then increased by 3.56% to $15.0 million in 2023, then fell by 14.9% to $12.7 million in 2024, then dropped by 14.84% to $10.9 million in 2025, then fell by 2.71% to $10.6 million in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Cash & Current Investments are $10.6 million (Q1 2026), $10.9 million (Q4 2025), and $10.7 million (Q3 2025).